

SECTION OF HEMATOLOGY/ONCOLOGY



SECTION CHIEF

Martha Mims, M.D., Ph.D.

The section of Hematology and Oncology has continued to grow in 2019 in our three missions of clinical care, education and research. In partnership with the Dan L Duncan Comprehensive Cancer Center, we welcomed three new clinical faculty members to solid tumor oncology, one to supportive oncology and two to our benign hematology group. We added an additional basic scientist to our group and one of our postdoctoral fellows joined as a tenure track faculty member. Our fellowship has grown to 22 fellows, with plans to increase by two more in the coming year. More than half of our senior fellows trained in basic science labs in 2019 and we continue to train graduate students and postdoctoral fellows. Our laboratory-based and clinical research programs have continued to grow with increasing grant and clinical

trials support. The section continues to educate students, residents and fellows from the classroom to the bedside and a number of our faculty have been awarded Norton Rose Fulbright Awards for these efforts. The section looks forward to continued growth in all of our programs in 2020.

A handwritten signature in black ink that reads "Martha Mims". The script is fluid and cursive.

Martha P. Mims, M.D., Ph.D.
Professor of Medicine
Section Chief, Hematology/Oncology

HIGHLIGHTS

Education

- The 2nd Annual Hematologic Malignancies Symposium with national and international speakers on myeloid malignancies (Gustavo Rivero, Chair)
- 2019 MD Anderson Cancer Center/Baylor College of Medicine Hematology and Medical Oncology Board Review (Martha Mims, BCM Chair)
- Chair of the ABIM Hematology Board (Mark Udden)

Research

- Minority PDX Development and Trial Center U54 (Nicholas Mitsiades and Matthew Ellis, PIs)
- CPRIT recruitment grants for Valentina Hoyos, Ang Li, and Gloria Echeverria
- AACR Distinguished Award for Extraordinary Scientific Achievement and Leadership in Breast Cancer Research (Kent Osborne)

Clinical Care

- Three "top doctors" (Musher, Carrum, Mims)
- Two early career awards for excellence in patient care (Miller-Chism, Sad)

FACULTY

Primary Faculty

- Charu Agrawal, M.D.
- Tannaz Armaghany, M.D.
- Malcolm K. Brenner, M.D.
- Michael Byrd, N.P.
- Sita Bushan, M.D.
- George Carrum, M.D.
- Margaret G. Crawford, M.S.N., B.S.N.
- Chad Creighton, M.D.
- Gloria Echeverria, M.D.
- Hazem El Osta, M.D.
- Matthew J. Ellis, M.D.
- Suzanne A. W. Fuqua, M.D.
- Helen E. Heslop, M.D.
- Laquisa Hill, M.D.
- Susan Galloway Hilsendbeck, M.D.
- Valentina Hoyos, M.D.
- Quillan Huang, M.D.
- Aparna Jotwani, M.D.
- Rammurti T. Kamble, M.D.
- Salma Kaochar, Ph.D.
- Jan Kemnade, M.D.
- Manila Kumar, N.P.
- Fang-Tsyr Lin, M.D., Ph.D.
- Weei-Chin Lin, M.D., Ph.D.
- Hao Liu, M.D.
- Premal Lulla, M.D.
- Courtney N. Miller-Chism, M.D.
- Martha Mims, M.D., Ph.D.
- Nicholas Mitsiades, M.D., Ph.D.
- Benjamin L. Musher, M.D.
- Julie Nangia, M.D.
- C. Kent Osborne, M.D.
- Carlos A. Ramos, M.D.
- Mothaffar F. Rimawi, M.D.
- Gustavo A. Rivero, M.D.
- Anita L. Sabichi, M.D.
- Yvonne H. Sada, M.D.
- Rachel Schiff, M.D.
- Maryam Nemati Shafee, M.D.
- Brandon G. Smaglo, M.D.
- Masataka Suzuki, M.D.
- Sravanti P. Teegavarapu, M.D.
- Perumal Thiagarajan, M.D.
- Mark M. Udden, M.D.
- Juan Vera Valdez, M.D.
- Daniel Y. Wang, M.D.
- Tao Wang, M.D.
- Norihiro Watanabe, M.D.
- Zahida Yasin, M.D.
- Sarvari V. Yellapragada, M.D.
- Aihua E. Yen, M.D.

Emeritus Faculty

- Gerald S. Cyprus, M.D.
- Teresa Hayes, M.D.
- Edward C. Lynch, M.D.
- Garrett R. Lynch, M.D.
- Joel L. Moake, M.D.
- David A. Spears, M.D.
- Robert F. Todd III, M.D.

Adjunct Faculty

- Powel H. Brown, M.D.
- Elizabeth Rogg, M.D.

RESEARCH ACTIVITIES

Chammness, Gary, M.D.

- Yr5: NRG Oncology Biospecimen Bank; NIH; \$50,976
- A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy in Rectal Cancer (The “G1002 Project”); NSABP; \$7,026

Creighton, Chad, M.D.

- Subaward: Prostate Epithelial Lineage Hierarchy; NIH (R01); \$10,871
- Molecular Mechanisms of Initiation of Benign Prostatic Hyperplasia; NIH (R01); \$10,645

Ellis, Matthew, M.D.

- Yr 5 – BR003-A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin in Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer; Breast Cancer Research Foundation; \$208,333
- Yr 5 – BR003-A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin in Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer; Breast Cancer Research Foundation (amend3 NSABP); \$85,550
- Yr 3: (MPI – U01) Microscaled Proteogenomics for Cancer Clinical Trials (Cptac); NIH U01-CA214125; \$1,167,618
- Yr 3: (MPI – U01) Microscaled Proteogenomics for Cancer Clinical Trials (Cptac); NIH U01-CA214125 -03 Amend 2_DU_Hyslop_PO 7000000435; \$16,109
- Yr 3: (MPI – U01) Microscaled Proteogenomics for Cancer Clinical Trials (Cptac); NIH U01-CA214125 -03 Amend 2_Mayo_Suman_PO 7000000469; \$16,377
- Yr 3: (MPI – U01) Microscaled Proteogenomics for Cancer Clinical Trials (Cptac); NIH U01-CA214125 -03 Amend 2_UNC_Perou_PO 7000000410; \$32,673
- Yr 3: (MPI – U01) Microscaled Proteogenomics for Cancer Clinical Trials (Cptac); NIH U01-CA214125 -03 Amend 5_Broad_Carr_PO 7000000403; \$770,632
- Mismatch Repair Defects and Endocrine Therapy Resistance in Er+ Breast Cancer; Susan G Komen Breast Cancer Foundation; \$6,000
- Proteogenomics of Endocrine Therapy Resistance; Susan G Komen Breast Cancer Foundation 1; \$320,000
- Yr 1: BC151851: Project 1: Direct Regulation of Estrogen Receptor Transcriptional Activity by Nf; United States Army Medical Research & Materiel Command (DOD); \$102,841

Fuqua, Suzanne, M.D.

- Yr 5: Role of ESR1 Mutations in Breast Cancer Progression; Breast Cancer Research Foundation; \$208,333
- Project 2: Overcoming Endocrine Insensitivity in Er-Positive Breast Cancer Patients; CPRIT; \$218,500
- Yr 20: Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer; NCI; \$202,500
- Yr 3: Mechanisms of AR-ER Collaboration in Hormone Resistance and Metastasis of Breast Cancer; NIH; \$221,887

- Yr 1: T32 Translational Breast Cancer Research Training Program; NIH; \$180,114

Hoyos, Valentina, M.D.

- Yr 1: Recruitment of First-Time, Tenure Track Faculty Member Dr. Valentina Hoyos Velez (Rft); CPRIT; \$467,778

Kaochar, Salma, M.D.

- After the Fact Submission - Characterization of First-in-Class Oncometabolic Inhibitor FGH; Biotech, Inc.; \$140,600
- Targeting the P160 Steroid Receptor Coactivators (SRCs) in African American Prostate Cancer; Prostate Cancer Foundation; \$75,000

Kavuri, Meghashyam, M.D.

- BC170466: Targeting DDR1 Aberrations in Metastatic Er+ Breast Cancer; Department of Defense Congressionally Directed Medical Research Programs; \$250,000
- Yr 1: Kinome Analysis to Rationalize Targeting Her2 and DDR1 Breast Cancer Mutations; Susan G Komen Breast Cancer Foundation; \$130,000
- Yr 2 - BC170276P1 Mismatch Repair Loss Renders Er+/Her2- Breast Cancer Susceptible to Her2/3 Inhibition; United States Army Medical Research & Materiel Command (DOD); \$98,140

Lapteva, Natalia, M.D.

- Pact Lovo Study; NHLBI; \$50,455

Lin, Weei-Chin, M.D.

- Exploiting a New Achilles Heel of Mutant P53 in Breast Cancer; Department of Defense Congressionally Directed Medical Programs; \$250,000
- Yr 15: The Atm/E2F1 Pathway in DNA Damage and Growth Control; NIH (R01); \$218,250
- Yr 3: MPI-Novel Therapeutics for Targeting Checkpoint Dysfunction in Cancer; NIH (R01); \$221,887
- Yr 5 - BCM Oncology Scholars Training Program; NIH; \$239,811

Lulla, Premal, M.D.

- Safety and Efficacy of Adoptively Transferred Multitaa Specific T Cells to Patients with Multiple Myeloma; American Society of Hematology; \$75,000
- Tailoring a T Cell Therapy to Patients with MDS; Edward P. Evans Foundation; \$181,818

Mitsiades, Nicholas, M.D.

- Translational Research in Breast Cancer (SPORE) Project 2: PKC-Mediated Inhibition of SRC-3 for the Treatment of ER+ Breast Cancer; \$173,917
- Developing transgenic animal models to address the role of GATA2 in prostate cancer; \$202,210
- Regulation of Uveal Melanoma Cell Fate by the PKC Pathway via MTF; \$228,750
- Targeting SPOP; \$169,391
- A First-in-Field Approach to Target a Previously Undruggable Oncogene Family in Prostate Cancer; \$200,000
- Sensitization of Castration Resistant Prostate Cancer to Chemotherapy via BRCA-1/BRCA-2 Induced DNA Replication Stress; Department of Defense Congressionally Directed Medical Research Programs; \$200,00

- Developing SPOP Inhibitors; Diana Helis Henry Medical Research Foundation Cancer Program; \$190,810
- Yr 4: Regulation of Uveal Melanoma Cell Fate by MITF via the PKC Pathway; NCI (R01); \$228,750
- Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer; NIH; U54-CA233223-01; \$4,207,746
- Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer; NIH U54-CA233223-01 Agreement_MDA_Navone_PO 7000000930; \$161,824

Nangia, Julie, M.D.

- 2019-2020 Pink for Life: Facilitating Breast Cancer Prevention and Treatment in Underserved & Minority Women; Susan G Komen; \$40,000

Nemati Shafae, Maryam, M.D.

- Astrazeneca – Breast Cancer Research and Education Program; Astrazeneca; \$3,000

Osborne, C. Kent, M.D.

- Yr 12: Baylor College of Medicine Cancer Center; NCI; \$2,020,895
- 12S4: Deep Phenotyping and Pan-Omics of Acute Lymphoblastic Leukemia in Down Syndrome (Assist Id #350407); NCI; \$447,705
- 12S4: Deep Phenotyping and Pan-Omics of Acute Lymphoblastic Leukemia in Down Syndrome (Assist Id #350407); NCI; \$181,638
- 12S1 Underrepresented High School and Undergraduate Student Research Experiences (Cure) Prior Year: 10S3 - (Brain 23664-S36), Prior Year: 11S2- (Brain 23664-S47); NCI; \$75,000
- 12S2_Year 2: NCI Moonshot Initiative: Administrative Supplements for the P30 Cancer Center Support Grant to Develop Tobacco Cessation Treatment Capacity and Infrastructure for Cancer Patients Previous Year 23664-S46; NCI; \$157,727
- 12S3 Administrative Supplement to Strengthen NCI-Supported Community Outreach Capacity Through Community Health Educators of the National Outreach Network Prior Year: 11S1 (Brain 23664-S48); NCI; \$78,867

Ramos, Carlos, M.D.

- Amendment: HPV 16/18 E6/E7- Specific T Cells for Treatment of HPV-Associated Cancers; Tessa Therapeutics Pte. LTD.; \$356,003

Rimawi, Mothaffar, M.D.

- Pink for Life - Expanding and Improving Breast Cancer Care and Prevention in Minority and Economically Disadvantaged Women; Avon Foundation; \$22,727
- Pink For Life - Expanding and Improving Breast Cancer Care and Prevention in Minority and Economically Disadvantaged Women; Avon Foundation; \$45,455
- Translational Breast Cancer Research Consortium Infrastructure Support Task Order; Breast Cancer Research Foundation; \$30,000
- A New Paradigm for De-Escalation of Treatment in Her2 Positive Breast Cancer: Revolutionizing Care with More Effective and Less Toxic Therapy; Department of Defense Congressionally Directed Medical Research Programs; \$314,641

- Translational Breast Cancer Research Consortium Infrastructure Support Task Order: Susan G. Komen Foundation; Susan G Komen Breast Cancer Foundation; \$28,125

Schiff, Rachel, M.D.

- Mechanisms of Resistance to Her2 and ER-Targeted Therapies and Novel Therapeutic Strategies; Breast Cancer Research Foundation; \$208,333
- Targeting the Mechanism of Hyperactive Foxa1 in Transcriptional Reprogramming Toward Endocrine Resistance and Metastasis in Breast Cancer; CPRIT; \$284,863
- NLK as Attractive Drug Target for Intractable Breast Cancer? (5R01Ca18136); NIH (R01); \$15,018
- Evaluate the Therapeutic Efficacy of Neratinib in Combination with Trastuzumab for Her2-Positive Breast Cancer Puma; Biotechnology Inc.; \$74,074
- A New Paradigm for De-Escalation of Treatment in Her2 Positive Breast Cancer: Revolutionizing Care with More Effective and Less Toxic Therapy; U.S. Army Medical Research & Materiel Command (Department of Defense); \$833,990
- A New Paradigm for De-escalation of Treatment in Her2 Positive Breast Cancer: Revolutionizing Care with More Effective and Less Toxic Therapy; U.S. Army Medical Research & Material Command (Department of Defense) (amend1 MSKCC); \$194,137

Suzuki, Masataka, M.D.

- Combinatorial Treatment with Armed Oncolytic Ad Gene Therapy and Car T-Cell Therapy for Squamous Cell Carcinoma of the Head and Neck (HNSCC); Tessa Therapeutics Pte. Ltd.; \$389,000
- Pre-Clinical Study of GPC3-Car Advsts; Tessa Therapeutics; \$250,001
- Grant Funding for Manpower Costs for Tessa Projects; Tessa Therapeutics Pte. Ltd.; \$128,199

Vera Valdez, Juan, M.D.

- Engineered T-Cell Therapy for Advanced Prostate Cancer; American Cancer Society; \$130,899
- Administration of Donor-Derived Multi-Tumor-Associated Antigen (Taa) – Specific T-Cells to Patients with AML or MDS (ADSPAM); Marker Therapeutics, LLC; \$160,375

Watanabe, Norihiro, M.D.

- Amendment #3: To Add an Additional Funds & Extend Term – Cook Regentec LLC SRA; Cook Regentec; \$28,536
- Amendment #5: To Add an Additional Funding to NCE – Cook Regentec LLC SRA; Cook Regentec; \$10,012
- Amendment #6: To Add Additional Funding to NCE – Cook Regentec LLC SRA; Cook Regentec

HONORS AND AWARDS

Carrum, George, M.D.

- Castle Connolly Top Doctors

Kaochar, Salma, M.D.

- 2018 Prostate Cancer Foundation Young Investigator Award

Miller-Chism, Courtney, M.D.

- Early Career Faculty Award for Excellence in Patient Care

Mims, Martha, M.D.

- Houstonia Magazine Top Doctor
- Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2018

Musher, Benjamin, M.D.

- “Top Doctor,” Harris Health System
- Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for GI Oncology Clinic; 2018
- *Houstonia Magazine* Top Doctor

Osborne, C. Kent, M.D.

- 2018 AACR Distinguished Award for Extraordinary Scientific Achievement and Leadership in Breast Cancer Research.

Rivero, Gustavo, M.D.

- Norton Rose Fulbright Faculty Excellence Award for Teaching and Evaluation

Sada, Yvonne, M.D.

- Early Career Faculty Award for Excellence in Patient Care

Sosa, Iberia, M.D.

- That’s The Way Player of the Month Award:
- Center of Excellence in Healthy Equity, Training, and Research Junior Faculty Scholar 2018-2019 Cohort

Udden, Mark, M.D.

- Chair, American Board of Internal Medicine Hematology Board
- Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2018